Skip to main content

Albireo Pharma, Inc. (ALBO)

NASDAQ: ALBO · IEX Real-Time Price · USD
23.16 -0.22 (-0.94%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap446.49M
Revenue (ttm)10.77M
Net Income (ttm)-47.87M
Shares Out19.28M
EPS (ttm)-2.50
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume124,760
Open23.62
Previous Close23.38
Day's Range22.86 - 23.82
52-Week Range21.51 - 43.41
Beta1.41
AnalystsStrong Buy
Price Target76.00 (+228.2%)
Earnings DateNov 4, 2021

About ALBO

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also d...

IndustryBiotechnology
CEORonald Cooper
Employees90
Stock ExchangeNASDAQ
Ticker SymbolALBO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Albireo Pharma stock is "Strong Buy." The 12-month stock price forecast is 76.00, which is an increase of 228.15% from the latest price.

Price Target
$76.00
(228.15% upside)
Analyst Consensus: Strong Buy

News

Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer

– New chief business officer to oversee Company's corporate and business development strategy – – New chief business officer to oversee Company's corporate and business development strategy –

6 days ago - GlobeNewsWire

Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Albireo Reports Q3 Financial Results and Business Update

– Bylvay™  (odevixibat) approved in the U.S. and Europe, partial Q3 '21 revenue of $1.1 million –

1 month ago - GlobeNewsWire

Albireo Pharma (ALBO) to Report Q3 Results: Wall Street Expects Earnings Growth

Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Albireo to Report Third Quarter 2021 Financial Results on November 4

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —

1 month ago - GlobeNewsWire

Albireo to Showcase New Data at AASLD The Liver Meeting® 2021

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –

1 month ago - GlobeNewsWire

Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan

– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –

1 month ago - GlobeNewsWire

Albireo Recognizes PFIC Awareness Day 2021

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Network ...

2 months ago - GlobeNewsWire

Albireo Announces Bylvay® (odevixibat) Now Available in Germany

– Listed on the German national price list and all pharmacy software programs –

2 months ago - GlobeNewsWire

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stoc...

3 months ago - GlobeNewsWire

Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –

3 months ago - GlobeNewsWire

Albireo Pharma Sells Bylvay-Associated PRV For $105M

Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million.  The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrah...

3 months ago - Benzinga

Albireo to Present at Upcoming Investor Conferences

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President a...

3 months ago - GlobeNewsWire

Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region

– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –

3 months ago - GlobeNewsWire

ALBIREO PHARMA (ALBO) Reports Q2 Loss, Misses Revenue Estimates

ALBIREO PHARMA (ALBO) delivered earnings and revenue surprises of 1.04% and -6.47%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Albireo Reports Q2 Financial Results and Business Update

– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC –

4 months ago - GlobeNewsWire

Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference

BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Ex...

4 months ago - GlobeNewsWire

Albireo to Report Second Quarter 2021 Financial Results on August 5

— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —

4 months ago - GlobeNewsWire

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.

4 months ago - Zacks Investment Research

Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US

Just a day after European approval, Albireo Pharma Inc (NASDAQ: ALBO) has received FDA approval for Bylvay (odevixibat), the first drug approved to treat pruritus in all subtypes of progressive familial...

4 months ago - Benzinga

MULTIMEDIA UPDATE - Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients Wit...

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

4 months ago - GlobeNewsWire

Albireo Announces FDA Approval of Bylvay™ (odevixibat), the First Drug Treatment for Patients With Progressive Famili...

– Only once-daily drug indicated for the treatment of pruritus in PFIC –

4 months ago - GlobeNewsWire

Albireo (ALBO) Cholestasis Drug Bylvay Gets European Approval

Albireo's (ALBO) Bylvay becomes the first and only drug to treat progressive familial intrahepatic cholestasis, following its approval in Europe.

4 months ago - Zacks Investment Research

Albireo's Bylvay Scores European Nod For Rare Pediatric Liver Disease

The European Commission (EC) has approved Albireo Pharma Inc's (NASDAQ: ALBO) Bylvay (odevixibat) for all subtypes of progressive familial intrahepatic cholestasis (PFIC).  Bylvay is a potent, non-syste...

4 months ago - Benzinga

Albireo Receives European Marketing Authorization of Bylvay™ (odevixibat), the First Drug Treatment for Progressive F...

– First approval in the world of Bylvay for the treatment of PFIC –

4 months ago - GlobeNewsWire